Preventing Chronic wound infections with a novel, antibiotic Wound Irrigation Solution; relieving patients from pain, risk of amputations and ensuring large cost savings for all Healthcare Systems.

Projektinformationen

WoundRinse

ID Finanzhilfevereinbarung: 816119

DOI

10.3030/816119

Projekt abgeschlossen

EK-Unterschriftsdatum 9 Mai 2018

Startdatum 1 Juni 2018

Enddatum 30 November 2018

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

SOFTOX SOLUTIONS AS
Norway

Periodic Reporting for period 1 - WoundRinse (Preventing Chronic wound infections with a novel, antibiotic Wound Irrigation Solution; relieving patients from pain, risk of amputations and ensuring large cost savings for all Healthcare Systems.)

Berichtszeitraum: 2018-06-01 bis 2018-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

SoftOx Solutions AS is in the process of developing an antimicrobial solution for treatment of infection on tissue. With the solution’s unique effect, the company aims to replace the use of antibiotics with the use of the Company’s topical applications. SoftOx’ antimicrobial solutions are efficient towards biofilm embedded and planktonic bacteria, virus, spores and fungi. The antimicrobial solution has been tested for potential resistance-issues, and it has not been observed inducement of resistance. The company’s first product line includes both medical devices and drugs, fighting chronic and antimicrobial resistant infections in acute and chronic wounds.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Biocompatibility tests according to ISO guidelines, including relevant animal models, show that SoftOx antimicrobials are well tolerated and do not impede natural wound healing. Also, an animal study on horse legs showed significant reduction in bacterial burden, thus documenting effect in vivo. Hygiene hand-rub test of studies of 18 healthy volunteers’ (EN 1500) showed a Log 4 reduction of the E coli bacteria within 1 minute, demonstrating significant effect as a hand-disinfectant.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The challenges targeted are some of the major issues for modern medicine, namely antibiotic resistance, biofilm infections in chronic wounds and hospital acquired infections. The O’Neill Report estimates a cost of up to USD 100 trillion and 10 million deaths yearly if there is no new alternative to the present antibiotic within 2050. Chronic wounds with biofilm infections are estimated to affect as much as 40 million patients yearly (leading to two million amputations) worldwide with a treatment cost of USD 260 billion.
Hospital acquired infections affects between 7 - 12 percent of hospitalized patients and have become a major source for spreading antibiotic-resistant bacteria. Products derived from the SoftOx technology has proven during the project to have the potential to become effective tools to help combat several of these challenges and threats to human health.

Company Logo